Active Biotech: Year End Report 2021
09 Feb 2022 //
GLOBENEWSWIRE
First subject dosed in phase I clinical study with eye-drop laquinimod
10 Dec 2021 //
GLOBENEWSWIRE
CDMO Famar and Active Biotech Ink Clinical Manufacturing Deal
04 Feb 2021 //
PRESS RELEASE
Teva drops development of laquinimod
07 Sep 2018 //
PHARMA TIMES
Active Biotech regains rights of laquinimod from Teva
06 Sep 2018 //
BIOSPECTRUM
Teva finally dumps laquinimod, ending failure-riddled saga
05 Sep 2018 //
FIERCE BIOTECH
Teva’s one-time blockbuster-to-be laquinimod fails yet again
31 Jul 2018 //
ENDPTS